Biocon532523Pharmaceuticals, biosimilars
Live TV News Channel's KYC segment gave Biocon a rating of 5.5 out of 8 based on financial and business analysis
By ScoutQuest · · 1 min read
- Final KYC rating
- 5.5 out of 8
- Analysts tracking stock
- 19 analysts
- Analysts with buy or hold rating
- two-third of analysts
Heard on business television between 11:51:20 - 11:54:20 IST.
- Host said management commentary was strong especially on H2 outlook due to key products and operational efficiency
- Noted income statement had lumpiness and mixed numbers this quarter
- Said balance sheet management was strong, rated with a thumbs up
- Noted cash flow had lumpiness due to expansions and deferral of revenues
- Said stock returns over last five years have not been major for investors, though valuations are fairly decent and analysts are bullish
- Said out of 19 analysts tracking the stock, two-thirds have buy or hold rating with a decent 12-month target price
- Final rating given as 5.5 out of 8, described as an average score that could change in future
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Biocon
Biocon to meet analysts at JM Financial and Avendus Spark conferences on 17-18 November 2026
11 Nov 2026
Q2 FY27 call: Pebrilzo launch dates secured, over $100 million new North America contracts
11 Nov 2026
Biocon's executive chairperson Kiran Mazumdar Shaw said H2 FY will see much stronger growth than H1, driven by biosimilars, insulin and new launches
5 Nov 2026
Source: Live TV News Channel · 5 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.